Table 2.
Number of upregulated and downregulated gene signatures for 35 anticancer compounds (55 treatment samples)
| Treatment sample ID | Compound | Upregulated × 3† (×2‡) | Downregulated × 3† (×2‡) |
|---|---|---|---|
| GR001 | Cisplatin | 19 (256) | 52 (697) |
| GR002 | Trichostatin A | 232 (1427) | 181 (1238) |
| GR003 | Vorinostat | 233 (1389) | 173 (1245) |
| GR004 | Bortezomib | 94 (494) | 68 (659) |
| GR005 | MG‐132 | 63 (428) | 51 (583) |
| GR006 | Geldanamycin | 0 (29) | 0 (32) |
| GR007 | 17‐AAG | 7 (68) | 0 (41) |
| GR008 | Vincristine | 0 (45) | 0 (6) |
| GR009 | Paclitaxel | 0 (41) | 0 (9) |
| GR010 | Docetaxel | 1 (37) | 0 (8) |
| GR011 | 5‐FU | 3 (131) | 14 (154) |
| GR012 | Gemcitabine | 2 (26) | 5 (49) |
| GR013 | Melphalan | 85 (716) | 242 (1553) |
| GR014 | Mitomycin C | 3 (69) | 9 (252) |
| GR015 | Oxaliplatin | 0 (11) | 9 (81) |
| GR016 | Bleomycin | 0 (6) | 1 (5) |
| GR017 | Actinomycin D | 26 (294) | 188 (1384) |
| GR018 | Neocarzinostatin | 0 (57) | 2 (138) |
| GR019 | Methotrexate | 1 (28) | 8 (62) |
| GR020 | 6‐Mercaptopurine | 2 (38) | 2 (52) |
| GR021 | Temsirolimus | 10 (132) | 0 (24) |
| GR022 | Everolimus | 16 (162) | 0 (13) |
| GR023 | PP242 | 98 (788) | 37 (530) |
| GR024 | Nimustine | 7 (131) | 13 (318) |
| GR025 | SN38 (Irinotecan) | 75 (602) | 512 (2445) |
| GR026 | Camptothecin | 102 (735) | 809 (3151) |
| GR027 | Topotecan | 28 (576) | 190 (1268) |
| GR028 | Doxorubicin | 49 (459) | 184 (1323) |
| GR029 | Etoposide | 2 (41) | 7 (133) |
| GR030 | Mitoxantrone | 47 (312) | 179 (1408) |
| GR031 | Pemetrexed | 2 (16) | 5 (34) |
| GR032 | 2‐Deoxyglucose | 130 (586) | 16 (439) |
| GR033 | Tunicamycin | 209 (768) | 63 (673) |
| GR034 | Thapsigargin | 69 (323) | 3 (119) |
| GR035 | A23187 | 266 (986) | 86 (931) |
| GR036 | Vorinostat (16 h) | 434 (2142) | 478 (2057) |
| GR037 | Bortezomib (16 h) | 268 (1379) | 299 (1882) |
| GR038 | Vincristine (16 h) | 28 (293) | 77 (335) |
| GR039 | Paclitaxel (16 h) | 21 (263) | 60 (281) |
| GR040 | Docetaxel (16 h) | 18 (221) | 57 (270) |
| GR041 | 5‐FU (16 h) | 26 (543) | 39 (556) |
| GR042 | Mitomycin C (16 h) | 25 (404) | 57 (605) |
| GR043 | Vorinostat (16 h) | 297 (1543) | 229 (1444) |
| GR044 | Bortezomib (16 h) | 118 (596) | 97 (904) |
| GR045 | Vorinostat (16 h) | 462 (2266) | 465 (2106) |
| GR046 | Bortezomib (16 h) | 307 (1551) | 373 (1893) |
| GR047 | Gemcitabine (16 h) | 15 (339) | 8 (186) |
| GR048 | Oxaliplatin (16 h) | 7 (167) | 53 (410) |
| GR049 | Bleomycin (16 h) | 3 (23) | 7 (29) |
| GR050 | Neocarzinostatin (16 h) | 13 (255) | 9 (180) |
| GR051 | Methotrexate (16 h) | 67 (692) | 53 (507) |
| GR052 | 6‐Mercaptopurine (16 h) | 35 (388) | 9 (273) |
| GR053 | PP242 (16 h) | 192 (1206) | 106 (924) |
| GR054 | Etoposide (16 h) | 33 (456) | 31 (405) |
| GR055 | Pemetrexed (16 h) | 24 (400) | 8 (186) |
†Number of probe sets such that the treatment‐to‐control ratio is more than 3 or <1/3 and the larger signal intensity of treatment or control is 300 is shown. ‡Results when the threshold values are changed (2 or 1/2 for ratio, 100 for signal intensity). 17‐AAG, 17‐N‐allylamino‐17‐demethoxygeldanamycin; 5‐FU, 5‐fluorouracil.